The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
 
Naminatsu Takahara
No Relationships to Disclose
 
Hiroyuki Isayama
Speakers' Bureau - Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yousuke Nakai
Speakers' Bureau - Taiho Pharmaceutical; Yakult Honsha
 
Tatsuya Ioka
Consulting or Advisory Role - AstraZeneca Japan (Inst); Baxalta (Inst); JCRO (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Mochida Pharmaceutical Co. Ltd.; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Nihon Zouki (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Merck Serono
 
Masashi Kanai
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical; Yakult Honsha
 
Takashi Sasaki
Research Funding - Eisai; Kyowa Hakko Kirin; Merck Serono; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Eisai; Eisai; J-Pharma; Janssen; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; MSD; NanoCarrier; NanoCarrier; Novartis; Novartis; OncoTherapy Science; OncoTherapy Science; Ono Pharmaceutical; Ono Pharmaceutical; Shionogi; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zeria Pharmaceutical; Zeria Pharmaceutical
 
Kazuhiko Koike
Research Funding - Chugai Pharma; Takeda; Yakult Honsha